Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

At the New Mexico Cancer Center in Albuquerque, groundbreaking treatments and compassionate care are changing lives for men facing prostate cancer. With a team of dedicated specialists, their ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Researchers have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging. This innovative probe targets CD45, a marker abundantly expressed ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

American Oncology Institute (AOI) in collaboration with Nangia Specialty Hospital in Nagpur, has introduced the advanced Gallium generator marking a new chapter in precision medicine. It will enable ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00. Get the latest from The ...